Drug General Information
Drug ID	D0Z0AM
Former ID	DNCL001780
Drug Name	PSI-697
Drug Type	Small molecular drug
Indication	Atherosclerosis; Thrombosis [ICD9: 414.0, 440, 437.6, 453, 671.5, 671.9; ICD10:I70, I80-I82]		Phase 1	[521877]
Company	Pfizer
Structure		Download 2D MOL 3D MOL
Formula	C21H18ClNO3
PubChem Compound ID	12004316
Target and Pathway
Target(s)	P-selectin	Target Info	Inhibitor	[532283]
KEGG Pathway	Cell adhesion molecules (CAMs)
	Malaria
	Staphylococcus aureus infection
Pathway Interaction Database	IL4-mediated signaling events
	amb2 Integrin signaling
Reactome	Platelet degranulation
	Cell surface interactions at the vascular wall
WikiPathways	Human Complement System
	Spinal Cord Injury
	Cell surface interactions at the vascular wall
References
Ref 521877	ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health.
Ref 532283	Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.